David Ranson will be presenting the Deflexifol opportunity to potential investors in Singapore, Hong Kong and Shanghai as part of AusBiotech’s Asian Investment Series, March 21 – 28, 2017. See http://ausbiotechinvestment.com.au/ for more details.
Trial results presented at ASCO GI, 2...
A poster presentation by Professor Phil Clingan summarizing phase 1 results has been presented at the ASCO GI conference, San Francisco, January 19-21, 2017. J Clin Oncol 35, 2017 (suppl 4S; abstract TPS812)
Deflexifol is safer for patients
Preclinical evaluation of novel, all-in-one formulations of 5-fluorouracil and folinic acid with reduced toxicity profiles. Click to read this article.
Potent, with fewer side effects
Deflexifol (formerly Fluorodex) maintains in-vitro potency, overcomes incompatibility of 5-fluorouracil and folinic acid and may reduce phlebitis, catheter blockages and thromboembolic events. Development and assessment of novel all-in-one parenteral formulations with integrated anticoagulant properties for the concomitant delivery of 5-fluorouracil and calcium folinate. Read our article signalling improved patient outcomes from Deflexifol.
New hope for patients
New hope being offered by Deflexifol to chemotherapy patients. Read here about new hope for chemotherapy patients.
New way to use an older drug
Deflexifol is a new way of using an older drug. Read more.